TNSN93045A1 - Nouveaux composes actifs - Google Patents

Nouveaux composes actifs

Info

Publication number
TNSN93045A1
TNSN93045A1 TNTNSN93045A TNSN93045A TNSN93045A1 TN SN93045 A1 TNSN93045 A1 TN SN93045A1 TN TNSN93045 A TNTNSN93045 A TN TNSN93045A TN SN93045 A TNSN93045 A TN SN93045A TN SN93045 A1 TNSN93045 A1 TN SN93045A1
Authority
TN
Tunisia
Prior art keywords
carbohydrate
active compounds
immunogenic
peptide
new active
Prior art date
Application number
TNTNSN93045A
Other languages
English (en)
Inventor
Jondal Mikael
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9201338A external-priority patent/SE9201338D0/xx
Priority claimed from SE9202553A external-priority patent/SE9202553D0/xx
Priority claimed from SE9203897A external-priority patent/SE9203897D0/xx
Priority claimed from SE9301141A external-priority patent/SE9301141D0/xx
Application filed by Astra Ab filed Critical Astra Ab
Publication of TNSN93045A1 publication Critical patent/TNSN93045A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18Acyclic radicals, substituted by carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02Acyclic radicals, not substituted by cyclic structures
    • C07H15/04Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K9/00Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K9/00Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/605MHC molecules or ligands thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/62Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Abstract

LA PRESENTE INVENTION SE RAPPORTE A UNE CLASSE NOUVELLE DE COMPOSES BIOLOGIQUEMENT ACTIFS, A DES PROCEDES EN VUE DE LEUR PRODUCTION, ET A LEUR EMPLOI EN THERAPIE. PLUS PARTICULIEREMENT, L'INVENTION PORTE SUR DES CONJUGUES IMMUNOGENES UTILES POUR LA CREATION D'UNE IMMUNITE T LYMPHOCYTAIRE CONTRE DES STRUCTURES GLUCIDIQUES A ASSOCIATION TUMORALE OU CONTRE DES STRUCTURES GLUCIDIQUES EXPRIMEES SUR DES AGENTS INFECTIEUX ET/OU DES CELLULES HOTES INFECTEES. LEDIT CONJUGUE IMMUNOGENE COMPREND (1) UN ELEMENT PEPTIDE CAPABLE DE SE LIER A UNE MOLECULE MHC DE CLASSE 1 ; ET (ii) UN ELEMENT GLUCIDE AYANT LA SPECIFICITE IMMUNOGENE DE LADITE STRUCTURE GLUCIDIQUE
TNTNSN93045A 1992-04-28 1993-04-28 Nouveaux composes actifs TNSN93045A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE9201338A SE9201338D0 (sv) 1992-04-28 1992-04-28 New active compounds
SE9202553A SE9202553D0 (sv) 1992-09-07 1992-09-07 New active compounds ii
SE9203897A SE9203897D0 (sv) 1992-12-23 1992-12-23 New active compounds iii
SE9301141A SE9301141D0 (sv) 1993-04-06 1993-04-06 New active compounds iv

Publications (1)

Publication Number Publication Date
TNSN93045A1 true TNSN93045A1 (fr) 1994-03-17

Family

ID=27484749

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN93045A TNSN93045A1 (fr) 1992-04-28 1993-04-28 Nouveaux composes actifs

Country Status (19)

Country Link
US (2) US5807559A (fr)
EP (1) EP0675733B1 (fr)
JP (1) JPH07506358A (fr)
CN (1) CN1096032A (fr)
AT (1) ATE197903T1 (fr)
AU (1) AU676679B2 (fr)
CA (1) CA2134097A1 (fr)
DE (1) DE69329735T2 (fr)
DK (1) DK0675733T3 (fr)
ES (1) ES2155070T3 (fr)
GR (1) GR3035501T3 (fr)
IL (1) IL105503A (fr)
IS (1) IS4010A (fr)
MA (1) MA22885A1 (fr)
MY (1) MY108864A (fr)
PT (1) PT675733E (fr)
SI (1) SI9300223A (fr)
TN (1) TNSN93045A1 (fr)
WO (1) WO1993021948A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083929A (en) * 1991-05-06 2000-07-04 The Biomembrane Institute Extended type 1 chain glycosphingolipids as tumor-associated antigens
DE4436164A1 (de) * 1994-10-10 1996-04-11 Hoechst Ag Neue Kohlenhydratkonjugate als Inhibitoren der Zelladhäsion
US6548643B1 (en) 1994-11-16 2003-04-15 Austin Research Institute Antigen carbohydrate compounds and their use in immunotherapy
US6841543B1 (en) 1996-01-31 2005-01-11 President And Fellows Of Harvard College Methods of inhibiting production of T helper type 2 cytokines in human immune cells
US6218363B1 (en) * 1996-08-28 2001-04-17 Thomas Jefferson University MHC peptides and methods of use
WO1998015286A1 (fr) * 1996-10-08 1998-04-16 La Jolla Institute For Allergy & Immunology Lymphocytes t a cytolyse specifique des glucides
ES2265162T3 (es) * 1997-03-27 2007-02-01 Institut Pasteur Carbohidrato glucopeptido de antigeno multiple, vacuna que comprende el mismo y su utilizacion.
US20070237785A1 (en) * 1997-03-27 2007-10-11 Institut Pasteur Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof
JP4308918B2 (ja) 1997-04-16 2009-08-05 スローン−ケッタリング インスティトゥート フォア キャンサー リサーチ (2,6)−STエピトープクラスターを有するα−O−結合複合糖質、その製造方法および使用
US7550146B2 (en) * 1997-04-16 2009-06-23 Sloan-Kettering Institute For Cancer Research Glycopeptide conjugates and uses thereof
AUPO732997A0 (en) * 1997-06-12 1997-07-03 Csl Limited Ganglioside immunostimulating complexes and uses thereof
CA2324616A1 (fr) * 1998-03-25 1999-09-30 Sloan-Kettering Institute For Cancer Research Conjugues de glycopeptides a liaison o antigeniques trimeres, procedes de preparation et utilisation de ceux-ci
US7402307B2 (en) * 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
WO1999050392A1 (fr) 1998-03-31 1999-10-07 Geron Corporation Techniques et compositions permettant de faire apparaitre une reponse immunitaire a un antigene de telomerase
EP1073667A2 (fr) * 1998-04-28 2001-02-07 Galenica Pharmaceuticals, Inc. Conjugues d'antigene et de polysaccharide
US20030091546A1 (en) * 1998-11-12 2003-05-15 Barber Jack R. Methods of suppressing immune response by gene therapy
US7824687B2 (en) 1999-08-20 2010-11-02 Sloan-Kettering Institute For Cancer Research Clustered multi-antigenic carbohydrate constructs, methods for their preparation, and uses thereof
JP5111705B2 (ja) * 1999-08-20 2013-01-09 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ 新規な複合多糖、グリコアミノ酸、これらへの中間体、及びこれらの使用
US7854934B2 (en) * 1999-08-20 2010-12-21 Sloan-Kettering Institute For Cancer Research Glycoconjugates, glycoamino acids, intermediates thereto, and uses thereof
DE10005275A1 (de) * 2000-02-07 2001-08-09 Bayer Ag Neuartige Glycokonjugate
US20030049253A1 (en) * 2001-08-08 2003-03-13 Li Frank Q. Polymeric conjugates for delivery of MHC-recognized epitopes via peptide vaccines
UA79952C2 (en) * 2001-12-10 2007-08-10 Kabulesh Mafatlal Khamar MYCOBACTERIUM w APPLICATIONS FOR CANCER TREATMENT
WO2004069873A2 (fr) * 2003-02-06 2004-08-19 Tripep Ab Echangeurs de specificite glycosyles
EP1720567A2 (fr) * 2004-02-10 2006-11-15 Innate Pharma Composition et procede pour le traitement de carcinome
US20060263415A1 (en) 2005-05-05 2006-11-23 Sensient Flavors Inc. Production of beta-glucans and mannans
WO2007073486A2 (fr) 2005-12-20 2007-06-28 Duke University Procedes et compositions pour l'administration d'agents actifs a proprietes pharmacologiques ameliorees
EP2391635B1 (fr) 2009-01-28 2017-04-26 Epimmune Inc. Polypeptides de liaison de pan-dr et leurs utilisations
JP2013527753A (ja) 2010-03-23 2013-07-04 イントレキソン コーポレーション 治療タンパク質を条件的に発現するベクター、該ベクターを含む宿主細胞およびそれらの使用
EP2500033A1 (fr) 2011-03-17 2012-09-19 Institut Pasteur Procédé pour la préparation de plusieurs conjugués de carbohydrate de glycopeptide d'antigène
KR102081868B1 (ko) 2011-06-28 2020-02-26 이노비오 파마수티컬즈, 인크. 최소 침습 피부 전기천공 장치
EP2606897A1 (fr) * 2011-12-22 2013-06-26 Laboratorios Del. Dr. Esteve, S.A. Procédés et compositions pour le traitement des maladies causées par les virus enveloppés
EP3651795A4 (fr) * 2017-07-12 2021-05-26 The Board of Trustees of the Leland Stanford Junior University Compositions et méthodes pour le traitement de cancers présentant une mutation h3k27m

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2004744B (en) * 1977-09-28 1982-05-26 Sanderson A R Immonulogical preparations
CA1335883C (fr) * 1986-07-08 1995-06-13 Bryan Michael Longenecker Stimulation de la reponse immunitaire cellulaire
JP2921574B2 (ja) * 1988-02-01 1999-07-19 アメリカン・サイアナミド・カンパニー 接合体ワクチンの担体分子としてのt細胞のエピトープ
EP0400077A4 (en) * 1988-02-12 1990-12-27 The Regents Of The University Of California Use of synthetic peptides to generate and manipulate cellular immunity
US5229289A (en) * 1988-03-11 1993-07-20 The Biomembrane Institute Monoclonal antibodies and vaccine development directed to human cancer-associated antigens by immunization with animal and human and with synthetic carbohydrate-carrier conjugates
CA1337403C (fr) * 1988-03-28 1995-10-24 Biomembrane Institute (The) Methodes de production d'anticorps et induction de reponses immunitaires aux gangliosides associes aux tumeurs par immunisation avec des lactones de gangliosides
WO1991001146A1 (fr) * 1989-07-14 1991-02-07 Praxis Biologics, Inc. Cytokine et supports d'hormone pour vaccins conjugues
CA2067124A1 (fr) * 1989-08-28 1991-03-01 Patricia L. Domen Vecteurs cationises pour la production d'immunogene
GB8924438D0 (en) * 1989-10-31 1989-12-20 Hoffmann La Roche Vaccine composition
IT1237764B (it) * 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.

Also Published As

Publication number Publication date
DE69329735D1 (de) 2001-01-11
IS4010A (is) 1993-10-29
ES2155070T3 (es) 2001-05-01
MY108864A (en) 1996-11-30
GR3035501T3 (en) 2001-06-29
US6033669A (en) 2000-03-07
DK0675733T3 (da) 2001-05-07
AU4274693A (en) 1993-11-29
ATE197903T1 (de) 2000-12-15
CN1096032A (zh) 1994-12-07
IL105503A (en) 1999-05-09
DE69329735T2 (de) 2001-08-02
EP0675733A1 (fr) 1995-10-11
WO1993021948A1 (fr) 1993-11-11
MA22885A1 (fr) 1993-12-31
CA2134097A1 (fr) 1993-11-11
US5807559A (en) 1998-09-15
IL105503A0 (en) 1993-08-18
EP0675733B1 (fr) 2000-12-06
PT675733E (pt) 2001-05-31
SI9300223A (en) 1994-03-31
AU676679B2 (en) 1997-03-20
JPH07506358A (ja) 1995-07-13

Similar Documents

Publication Publication Date Title
MA22885A1 (fr) Nouveaux composes actifs.
BR9303469A (pt) Conjugado de interferon,composto,processo de preparacao de um conjugado de interferon,use e composicoes farmaceuticas
DE68906366D1 (en) Cd4-polypeptidderivate.
ES2056215T3 (es) Composiciones de detergente.
GR3026658T3 (en) Hydrazino-type radionuclide chelators having an n 3?s configuration
EP1003526A4 (fr) N, o-carboxymethyl-chitosane a liaison covalente et ses applications
ATE296105T1 (de) Iminbildende polysaccharide, deren herstellung und verwendung als zusatzmittel und immunstimulierende mittel
DK1137430T3 (da) Terapeutikum til undertrykkelse af snorkelyde
IL118603A (en) Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
WO1991017773A3 (fr) Nouveaux conjugues de proteines et de polycations
NZ506631A (en) Formulations for the stabilisation of PEG-interferon alpha conjugates during and after lyophilization
TR199501654A3 (fr)
TW218847B (fr)
DE69106361D1 (de) Einschlusskomplex von nimesulide mit cyclodextrinen.
AR016427A1 (es) CONJUGADOS uTILES PARA EL TRATAMIENTO DE CÁNCER DE PRoSTATA, Y UNA COMPOSICIoN FARMACÉUTICA QUE LOS COMPRENDE.
NZ235316A (en) Vaccine containing capsular polysaccharide conjugated to recombinant c protein of a group b streptococcus, production and use against b streptococcus infection
EP0378203A3 (fr) Acide-hydrazide de la cobalamine et conjugués de la cobalamine en dérivant
AU7299591A (en) Delivery of agents
JO1766B1 (en) Effective new compounds
TW332816B (en) Peptide and carbohydrate
FI961339A0 (fi) Triaryylieteenijohdannaiset käytettäväksi hoidossa
IT8820245A0 (it) Palmitoil_fruttosio_1,6_difosfato, suo uso terapeutico e relativi metodi di preparazione.
FR2652266B1 (fr) Vaccin protecteur contre l'hemophilose porcine.
TH13666A (th) สารประกอบออกฤทธิ์ชนิดใหม่
NO884941L (no) Konjugat av metallothionein eller et metallothioneinfragment og et maalsoekende biologisk aktivt molekyl, som er anvendelig som mellomprodukt ved fremstilling av lignende merkede konjugater.